A Multi-Center Study Subjects With Dry Eye Syndrome

Inclusion Criteria: * Provide written informed consent prior to any study related procedures * Are 18 years of age or older * Are women of child bearing potential (WOCBP) who are non-pregnant, non-lactating and sexually inactive (abstinent) for 14 days prior to Visit 1 * Are willing and able to follow instructions and can be present for the required study visits for the duration of the study * Have a history of Dry Eye Syndrome in both eyes supported by a previous clinical diagnosis * Have ongoing Dry Eye Syndrome, in the same eye or both eyes, as defined by the following criteria: 1. A score of ≥23 on OSDI 2. A corneal fluorescein staining score of ≥6 (NEI scale) * Have normal lid anatomy * Are willing to withhold artificial tears for the duration of the study, with the exception of the study provided artificial tears: Refresh Plus®. Exclusion Criteria: Subjects may not: * Have previously used an IL-1 blocker (e.g., Anakinra, Rilonacept or Ilaris). * Have an OSDI score ≥90 * Have a corneal fluorescein staining score of 15 (NEI scale). NOTE: If one of two eyes has a corneal fluorescein staining score of 15, the subject may be eligible. * Within 30 days prior to the screening visit (Visit 1) have taken: Topical cyclosporine (Restasis®) Ocular corticosteroids Autologous serum Topical ocular antibiotics Topical ocular antihistamines or mast cell stabilizers Topical or nasal vasoconstrictors * Within 30 days prior to the screening visit (Visit 1) have altered the dose of tetracycline compounds (tetracycline, doxycycline or minocycline).